Budget 2023Budget 2023


  • Tata AIA Life Insurance
  • Hafele
  • Motilal Oswal
Upcoming Event : LeapToUnicorn - mentoring, networking and fundraising for startups. Register now
Budget 2023
Budget 2023

Sun Pharma joins biosimilars race, to target assets with patent expiries in 7-10 years

Company chief Dilip Shanghvi, known for his midas touch in the pharma industry, has for years stayed away from biosimilars but now aims to spend between 8-9 percent of turnover on R&D.

May 28, 2021 / 04:08 PM IST
File image

File image

  • bselive
  • nselive
Todays L/H

Sun Pharma, India's largest drug maker, said it will be joining the race to develop biosimilar drugs.

"We are evaluating development of some biosimilars, which can be classified amongst the third wave," said Dilip Shanghvi, Managing Director, at the company's earnings call on May 27.

"I think we are looking at products, which have significant future patent expiry dates, we can be amongst the first approvals. That's the focus ... we are finding a way to leverage our presence in the that we can successfully build a biosimilars portfolio," he said.

Shanghvi anticipates a timeline of 2028-2030 for the proposed biosimilar assets to hit the market.